You are here » Home » Companies » Company Overview » Arvind Remedies Ltd

Arvind Remedies Ltd.

BSE: 531823 Sector: Health care
NSE: ARVINDREM ISIN Code: INE211C01037
BSE LIVE 15:02 | 13 Jun Stock Is Not Traded.
NSE LIVE 15:40 | 24 Sep Stock Is Not Traded.
OPEN 4.70
PREVIOUS CLOSE 4.94
VOLUME 2850
52-Week high 6.60
52-Week low 3.78
P/E
Mkt Cap.(Rs cr) 32.02
Buy Price 0.00
Buy Qty 0.00
Sell Price 4.70
Sell Qty 29739.00
OPEN 4.70
CLOSE 4.94
VOLUME 2850
52-Week high 6.60
52-Week low 3.78
P/E
Mkt Cap.(Rs cr) 32.02
Buy Price 0.00
Buy Qty 0.00
Sell Price 4.70
Sell Qty 29739.00

Arvind Remedies Ltd. (ARVINDREM) - Chairman Speech

Company chairman speech

CHAIRMANS STATEMENT

Dear Shareholders

FY 14 has been a good year for Arvind Remedies with growth in overall business andcommercialization of Unit 3 we are foraying our presence in the 1000cr Revenue mark. Weare much grateful to our esteemed shareholders for all their support and cooperationextended all along in the past. Our presence in Domestic market has increased to 30 ownbrands across acute and chronic segment. Currently our field force is covering 10 states.In the Generic segment we have a specialised team for In house sales & marketingpersonnel which has a good reach to Pan India. Going ahead we expect to explore moreopportunities to increase the number of product and the marketing territories for thedomestic segment. This year we have seen increase of contribution from the CRAMS segmentwhich we cater to various national and multinational companies in dosage forms of TabletsCapsules Dry Syrups Ointments Liquid Orals and Injectables. In the International marketwe are foraying into new regions and expect larger contributions in the marketing share inthe coming years. New products are also being developed with the patents registration.Looking at the need of drugs with less side effects and better efficacy we at ArvindRemedies are engaged in developments of dosage forms with unique USP. As a result sideeffect of existing formulation is reducing and bioavailability of drug or end pointtherapeutic effect is increasing. Currently we have products in the late clinical stage indifferent therapeutic segments like Neuro de-generation disorder Arthritis CardiacDepression and Viral Diseases. Needless to mention we look forward to your continuedsupport in bringing up ARL to the heights of global renown.

With good wishes

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard